Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10522832 | 1.00 | PTPN1 (0.48) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL13379049 | 1.00 | PTPN1 (0.48) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL13567845 | 0.92 | PTPN1 (0.43) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL15866138 | 0.91 | PTPN1 (0.45) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL9846453 | 0.91 | PTPN1 (0.45) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL5745374 | 0.91 | PTPN1 (0.45) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL18453426 | 0.90 | PTPN1 (0.44) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL4440958 | 0.90 | PTPN1 (0.44) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL22211568 | 0.87 | PTPN1 (0.42) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 | |
| SCHEMBL6358667 | 0.87 | PTPN1 (0.42) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| US-7485641-B2 | Substituted 3-amino-pyrrolidino-4-lactams | PFIZER, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2007148185-A2 | SUBSTITUTED 3 -AMINO- PYRROLIDINO-4 -LACTAMS AS DPP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PFIZER INC | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | PTPN1 1765/4885FUCA1 4824/4885DRD2 3837/4885 |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PRMT1, PRMT7, PRMT3 | PTPN1 1560/4885FUCA1 4528/4885DRD2 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.